sponsored
PatientsVille.com Logo

PatientsVille

Amlodipine Medical Research Studies

Up-to-date List of Amlodipine Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Amlodipine Medical Research Studies

Rank Status Study
1 Not yet recruiting CKD-330 Drug-Drug Interaction Study (Amlodipine)
Condition: Hypertension
Interventions: Drug: Amlodipine 10mg;   Drug: Amlodipine 10mg/Candesartan 32mg
Outcome Measures: AUCτ,ss of Amlodipine;   Cmax,ss of Amlodipine;   Tmax,ss of Amlodipine
2 Recruiting Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
Condition: Hypertension
Interventions: Drug: Amlodipine+Rosuvastatin;   Drug: GSK3074477 FDC - 1;   Drug: GSK3074477 FDC - 2
Outcome Measures: Plasma pharmacokinetics (PK) parameters of Amlodipine and rosuvastatin following single dose administration;   Additional PK parameters of Amlodipine and rosuvastatin following single dose administration;   Safety as assessed by adverse events;   Safety as assessed by vital signs;   Safety as assessed by clinical laboratory safety data;   Safety as assessed by Electrocardiogram (ECG) parameters
3 Not yet recruiting Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Amlodipine;   Drug: LCZ696 and Amlodipine combination;   Drug: Placebo
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (msSBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting systolic blood pressure (msSBP) of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone.;   Change from baseline in mean sitting Diastolic Blood Pressure (msDBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in pulse pressure;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Percentage of patients achieving msSBP <140 mmHg and msDBP <90 mmHg;   Percentage of patients achieving msSBP <140 mmHg or a reduction ≥20 mmHg from baseline;   Percentage of patients achieving msDBP <90 mmHg or a reduction ≥10 mmHg from baseline;   Number of patients reporting adverse events
4 Not yet recruiting Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group A);   Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group B);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group A);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group B)
Outcome Measures: Mean reduction of systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment);   Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment;   Percentage of subjects with controlled blood pressure under different dosages of after study treatment;   Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment;   Number of subjects with adverse events (AEs)
5 Not yet recruiting Bedtime Administration of Amlodipine Versus Lisinopril
Condition: Hypertension
Intervention: Drug: Amlodipine
Outcome Measures: Change in mean sleep-time systolic blood pressure after addition of a bedtime dose of Amlodipine versus lisinopril;   Changes in mean sleep-time diastolic, awake systolic and diastolic blood pressures, including comparison of % achieving target BP;   Impact of individual medications on sleep-time blood pressure drop (dipping status);   Association of baseline renin levels to sleep-time blood pressure drop;   Association of baseline renin levels with response to Amlodipine versus lisinopril;   Association of baseline dipping status with response to Amlodipine versus lisinopril;   Association of age and response to Amlodipine versus lisinopril
6 Recruiting Amlodipine for Myocardial Iron in Thalassemia
Condition: Thalassemia
Interventions: Drug: Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone);   Drug: Amlodipine
Outcome Measures: Efficacy of Amlodipine in retarding rate of myocardial iron deposition (Assessed by change in T2* times);   Effect of Amlodipine therapy on left ventricular size, systolic and diastolic function;   Efficacy of Amlodipine in retarding liver iron content (mg/g);   Adverse effects of Amlodipine therapy
7 Recruiting Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine-FA tablet,low dose group;   Drug: Amlodipine-FA tablet,high dose group;   Drug: Amlodipine
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
8 Recruiting Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine;   Drug: Amlodipine-FA tablet, low dose group;   Drug: Amlodipine-FA tablet ,high dose group
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
9 Recruiting Amlodipine Plus/Minus Atorvastatin for Protection of Arteries
Condition: Arterial and Arteriolar Disorders
Interventions: Drug: Amlodipine plus atorvastatin (Caduet);   Drug: Amlodipine (Norvasc)
Outcome Measures: flow-mediated dilation (FMD);   pulse wave velocity (cf-PWV, ba-PWV);   liver function;   ankle-brachial index (ABI);   augmentation index (AIx);   carotid intima-media thickness (IMT);   cholesterol level
10 Recruiting DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: AM 5 + DM 0;   Drug: AM 5 + DM 2.5;   Drug: AM 5 + DM 7.5;   Drug: AM 5 + DM 30
Outcome Measures: *SBP reduction=SBP each visit- SBPvisit2;   The secondary objectives of the study include: Efficacy/Safety
11 Recruiting A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Amlodipine 5mg;   Drug: Amlodipine 10mg;   Drug: Candesartan Cilexetil 8mg;   Drug: Candesartan cilexetil 16mg
Outcome Measures: Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline;   Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8;   Change in siDBP at week 4;   Proportion of patients achieving ΔsiDBP > 10 mmHg and ΔsiSBP < 20 mmHg after 8 weeks;   Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks
12 Recruiting Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Condition: Hypertension
Interventions: Drug: Amlodipine;   Drug: Losartan
Outcome Measures: SD of visit-to-visit systolic blood pressure variability;   Central systolic blood pressure;   Augmentation index of central blood pressure;   Standard deviation of within-visit systolic blood pressure variability;   Coefficient of variation of visit-to-visit systolic blood pressure variability;   Variation independent of the mean of visit-to-visit systolic blood pressure variability;   24-h ambulatory blood pressure monitoring;   Home systolic blood pressure
13 Not yet recruiting Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
Condition: Hypertension
Interventions: Drug: TELMINUVO Tab. (80/2.5mg);   Drug: TELMINUVO Tab. (80/5mg);   Drug: S-Amlodipine 2.5mg;   Drug: S-Amlodipine 5mg
Outcome Measures: Mean Sitting Systolic Blood Pressure (MSSBP);   Mean Sitting Diastolic Blood Pressure (MSDBP);   Control Rate;   Response Rate
14 Recruiting Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Condition: Hypertension
Interventions: Drug: Telmisartan;   Drug: Amlodipine;   Drug: Chlorthalidone
Outcome Measures: AUCt ss, Cmax ss of telmisartan/Amlodipine/chlorthalidone;   Cmin ss, tmax ss, t1/2 of telmisartan/Amlodipine/chlorthalidone
15 Unknown  A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients
Condition: Coronary Artery Disease
Interventions: Drug: Placebo;   Drug: Amlodipine
Outcome Measures: Exercise capacity;   Sublingual Nitrate;   Biomarkers
16 Recruiting Fimasartan/Amlodipine Combination Phase III
Condition: Essential Hypertension
Interventions: Drug: Fimasartan and Amlodipine;   Drug: Fimasartan
Outcome Measures: Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline;   Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline;   Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline;   Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration;   The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration
17 Recruiting Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
Condition: Coronary Artery Disease
Interventions: Drug: Ranolazine;   Drug: Amlodipine
Outcome Measures: Assessment of platelet reaction units;   Frequency of high platelet reactivity
18 Recruiting A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
Condition: Hypertension
Intervention: Drug: Fimasartan , Amlodipine, Placebo
Outcome Measures: Sitting Diastolic Blood Pressure;   Sitting Systolic Blood Pressure;   Responder ratio
19 Unknown  Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Amlodipine
Outcome Measures: Myocardial T2* values (msec);   Liver T2* values (msec);   Serum ferritin levels;   left ventricle volumes and function
20 Recruiting Intermittent Hypoxia 2: Cardiovascular and Metabolism
Conditions: Hypoxia;   Sleep Apnea;   Obstructive Sleep Apnea
Interventions: Drug: Placebo;   Drug: Valsartan;   Drug: Amlodipine
Outcome Measures: Change in sympathetic activity;   Measure of adrenergic, inflammatory and metabolic markers in adipose tissues by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure variations in parameters of inflammation in adipose tissue by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure of metabolic aspects of the OGTT test.;   Measure the activation of systemic inflammation by chronic HI versus placebo in healthy nonobese subjects. The systemic inflammation will be assessed in non-stress and during the OGTT.;   Assessing markers implicated in the pathophysiology of chronic metabolic diseases after HI versus placebo in healthy nonobese subjects during OGTT.;   Change in vascular responsivness;   Change in Sympathetic and vascular determinant of Blood pressure

These studies may lead to new treatments and are adding insight into Amlodipine etiology and treatment.

A major focus of Amlodipine research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Amlodipine